Skip to main content
Fig. 5 | BMC Musculoskeletal Disorders

Fig. 5

From: Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression

Fig. 5

rSOST impact on bone density. No systemic or localized changes in bone density were observed after rSOST treatment. There was no difference in initial or final bone density between the three groups. a Whole body BMD at the termination of the experiment (p = 0.19). b Terminal BMD of spine and pelvis only (p = 0.59). c Terminal right femur BMD (p = 0.62). d Initial whole body BMD measurement after four proteoglycan injections (p = 0.46). e Whole animal BMD by treatment group at each time point (p = 0.7)

Back to article page